Preclinical and first-in-human phase I studies of KW-2450, an oral tyrosine kinase inhibitor with insulin-like growth factor receptor-1/insulin receptor selectivity

Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors.

(2017) J. Desai et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors.

(2017) W. A. Harb et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.

(2017) V. M. Macaulay et al.   JOURNAL OF CLINICAL ONCOLOGY

Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study

(2015) Martin Fassnacht et al.   LANCET ONCOLOGY

Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors

(2014) R. L. Jones et al.   CLINICAL CANCER RESEARCH

A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors

(2014) I. Puzanov et al.   CLINICAL CANCER RESEARCH

A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer

(2014) Johanna C. Bendell et al.   INVESTIGATIONAL NEW DRUGS

Regorafenib for Gastrointestinal Malignancies

(2013) Giuseppe Aprile et al.   BIODRUGS

Vandetanib for the Treatment of Medullary Thyroid Cancer

(2012) N. G. Chau et al.   CLINICAL CANCER RESEARCH

The Insulin Receptor/Insulin-Like Growth Factor Receptor Family as a Therapeutic Target in Oncology

(2012) M. Pollak   CLINICAL CANCER RESEARCH

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

(2012) Jorge E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

(2011) Brian I Rini et al.   LANCET

Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy

(2011) Erin R. King et al.   Recent Patents on Anti-Cancer Drug Discovery

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT

(2010) D Handolias et al.   BRITISH JOURNAL OF CANCER

Pazopanib in Renal Cell Carcinoma

(2010) J. E. Ward et al.   CLINICAL CANCER RESEARCH

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates

(2010) Patrick A. Ott et al.   PLoS One

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

(2009) Thomas O'Hare et al.   CANCER CELL

Targeting the IGF1 axis in cancer proliferation

(2009) Ilan Bruchim et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor

(2009) Mark J Mulvihill et al.   Future Medicinal Chemistry

Insulin-like growth factor receptor type I as a target for cancer therapy

(2009) Liliane Goetsch et al.   Immunotherapy

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR

(2009) J. M. Carboni et al.   MOLECULAR CANCER THERAPEUTICS

The Type 1 Insulin-Like Growth Factor Receptor Pathway

(2008) M. M. Chitnis et al.   CLINICAL CANCER RESEARCH

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE